Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...